Recent Advances in Tumor Ablation for Hepatocellular Carcinoma

Liver Cancer

Volumn 4, Issue 3, 2015, Pages 176-187

  Kang, Tae Wook ^a   Rhim, Hyunchul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Diagnosis; Hepatocellular carcinoma; Image guided tumor ablation; Treatment outcome

Indexed keywords

CONTRAST MEDIUM; DOXORUBICIN; GADOXETIC ACID; PERFLUBUTANE; PERFLUTREN; SHU 508;

CANCER CONTROL; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; ECHOGRAPHY; ELECTROPORATION; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LIVER CELL CARCINOMA; MICROWAVE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR ABLATION;

EID: 84992226705     PISSN: 22351795     EISSN: 16645553     Source Type: Journal    
DOI: 10.1159/000367740     Document Type: Review

References (77)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Alazawi W, Cunningham M, Dearden J, Foster GR: Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther 2010;32:344-355.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
4. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
5. European Association For The Study Of The Liver European Organisation For Research And Treatment Of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
6. Lee JM, Park JW, Choi BI: 2014 KLCSG-NCC Korea Practice Guidelines for the management of hepatocellular carcinoma: HCC diagnostic algorithm. Dig Dis 2014;32:764-777.
7. Lin SM: Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer 2013;2:73-83.
8. Pereira PL: Actual role of radiofrequency ablation of liver metastases. Eur Radiol 2007;17:2062-2070.
9. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, Adema GJ: In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004;64:4024-4029.
10. Figueiredo C, Wittmann M, Wang D, Dressel R, Seltsam A, Blasczyk R, Eiz-Vesper B: Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood 2009;113:3008-3016.
11. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, Boerman OC, Figdor CG, Ruers TJ, Adema GJ: Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 2006;95:896-905.
12. Haen SP, Gouttefangeas C, Schmidt D, Boss A, Clasen S, von Herbay A, Kosan B, Aebert H, Pereira PL, Rammensee HG: Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones 2011;16:495-504.
13. Ahmad F, Gravante G, Bhardwaj N, Strickland A, Basit R, West K, Sorge R, Dennison AR, Lloyd DM: Changes in interleukin-1? and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections. Am J Surg 2010;200:500-506.
14. Dong BW, Zhang J, Liang P, Yu XL, Su L, Yu DJ, Ji XL, Yu G: Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia 2003;19:119-133.
15. Chu KF, Dupuy DE: Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014;14:199-208.
16. Jansen MC, van Hillegersberg R, Schoots IG, Levi M, Beek JF, Crezee H, van Gulik TM: Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery 2010;147:686-695.
17. Chapman WC, Debelak JP, Blackwell TS, Gainer KA, Christman JW, Pinson CW, Brigham KL, Parker RE: Hepatic cryoablation-induced acute lung injury: Pulmonary hemodynamic and permeability effects in a sheep model. Arch Surg 2000;135:667-672; discussion 672-663.
18. Schlief R, Schurman R, Niendorf HP: Basic properties and results of clinical trials of ultrasound contrast agents based on galactose. Ann Acad Med Singapore 1993;22:762-767.
19. Wen YL, Kudo M, Zheng RQ, Ding H, Zhou P, Minami Y, Chung H, Kitano M, Kawasaki T, Maekawa K: Characterization of hepatic tumors: value of contrast-enhanced coded phase-inversion harmonic angio. AJR Am J Roentgenol 2004;182:1019-1026.
20. Leen E, Angerson WJ, Yarmenitis S, Bongartz G, Blomley M, Del Maschio A, Summaria V, Maresca G, Pezzoli C, Llull JB: Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002;41:200-206.
21. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T: Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J Gastroenterol 2011;106:368-370.
22. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M, HCC Expert Panel of Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
23. Lee JM, Yoon JH, Joo I, Woo HS: Recent advances in ct and mr imaging for evaluation of hepatocellular carcinoma. Liver Cancer 2012;1:22-40.
24. Park JH, Kim SH, Park HS, Kim GH, Lee JY, Lee JM, Han JK, Choi BI: Added value of 80 kVp images to averaged 120 kVp images in the detection of hepatocellular carcinomas in liver transplantation candidates using dual-source dual-energy MDCT: results of JAFROC analysis. Eur J Radiol 2011;80:e76-e85.
25. Marin D, Nelson RC, Schindera ST, Richard S, Youngblood RS, Yoshizumi TT, Samei E: Low-tube-voltage, high-tube-current multidetector abdominal CT: improved image quality and decreased radiation dose with adaptive statistical iterative reconstruction algorithm-initial clinical experience. Radiology 2010;254:145-153.
26. Lee SH, Lee JM, Kim KW, Klotz E, Kim SH, Lee JY, Han JK, Choi BI: Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol 2011;46:77-84.
27. Thian YL, Riddell AM, Koh DM: Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging 2013;13:567-579.
28. Van Beers BE, Pastor CM, Hussain HK: Primovist, Eovist: what to expect? J Hepatol 2012;57:421-429.
29. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K: Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging-correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255:824-833.
30. Lee SA, Lee CH, Jung WY, Lee J, Choi JW, Kim KA, Park CM: Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011;29:83-90.
31. Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, Choi BI: Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013;267:776-786.
32. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, Choi D, Rhim H: Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012;264:761-770.
33. Yu MH, Kim JH, Yoon JH, Kim HC, Chung JW, Han JK, Choi BI: Small (?1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 2014;271:748-760.
34. Hwang J, Kim SH, Lee MW, Lee JY: Small (? 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3. 0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 2012;85:e314-e322.
35. Lee MW: Fusion imaging of real-time ultrasonography with CT or MRI for hepatic intervention. Ultrasonography 2014;33:227-239.
36. Minami Y, Chung H, Kudo M, Kitai S, Takahashi S, Inoue T, Ueshima K, Shiozaki H: Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. AJR Am J Roentgenol 2008;190:W335-341.
37. Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK: Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR Am J Roentgenol 2013;201:1141-1147.
38. Lee MW, Kim YJ, Park HS, Yu NC, Jung SI, Ko SY, Jeon HJ: Targeted sonography for small hepatocellular carcinoma discovered by CT or MRI: factors affecting sonographic detection. AJR Am J Roentgenol 2010;194:W396-400.
39. Lee MW, Rhim H, Cha DI, Kim YJ, Lim HK: Planning US for percutaneous radiofrequency ablation of small hepatocellular carcinomas (1-3 cm): value of fusion imaging with conventional US and CT/MR images. J Vasc Interv Radiol 2013;24:958-965.
40. Kunishi Y, Numata K, Morimoto M, Okada M, Kaneko T, Maeda S, Tanaka K: Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol 2012;198:106-114.
41. Lim S, Lee MW, Rhim H, Cha DI, Kang TW, Min JH, Song KD, Choi SY, Lim HK: Mistargeting after fusion imaging-guided percutaneous radiofrequency ablation of hepatocellular carcinomas. J Vasc Interv Radiol 2014;25:307-314.
42. Hakime A, Deschamps F, De Carvalho EG, Barah A, Auperin A, De Baere T: Electromagnetic-tracked biopsy under ultrasound guidance: preliminary results. Cardiovasc Intervent Radiol 2012;35:898-905.
43. Tomonari A, Tsuji K, Yamazaki H, Aoki H, Kang JH, Kodama Y, Sakurai Y, Maguchi H: Feasibility of the virtual needle tracking system for percutaneous radiofrequency ablation of hepatocellular carcinoma. Hepatol Res 2013;43:1352-1355.
44. Kang TW, Lee MW, Choi SH, Rhim H, Lim S, Song KD, Min JH, Choi SY, Lim HK, Yang J: A novel electrode with electromagnetic tip tracking in ultrasonography-guided radiofrequency ablation: A phantom, ex vivo, and in vivo experimental study. Invest Radiol 2015;50:81-87.
45. Hakime A, Barah A, Deschamps F, Farouil G, Joskin J, Tselikas L, Auperin A, de Baere T: Prospective comparison of freehand and electromagnetic needle tracking for US-guided percutaneous liver biopsy. J Vasc Interv Radiol 2013;24:1682-1689.
46. Ewertsen C, Nielsen KR, Nielsen MB: Freehand biopsy guided by electromagnetic needle tracking: a phantom study. Ultraschall Med 2011;32:614-618.
47. Al Knawy B, Shiffman M: Percutaneous liver biopsy in clinical practice. Liver Int 2007;27:1166-1173.
48. Minami Y, Kudo M: Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol 2011;17:4952-4959.
49. Min JH, Lim HK, Lim S, Kang TW, Song KD, Choi SY, Rhim H, Lee MW: Radiofrequency ablation of very-earlystage hepatocellular carcinoma inconspicuous on fusion imaging with B-mode US: value of fusion imaging with contrast-enhanced US. Clin Mol Hepatol 2014;20:61-70.
50. Nishigaki Y, Hayashi H, Tomita E, Suzuki Y, Watanabe N, Watanabe S, Watanabe C, Takagi Y, Kato T, Naiki T: Usefulness of contrast-enhanced ultrasonography using sonazoid for the assessment of therapeutic response to percutaneous radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2015;45:432-440.
51. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L: Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158-171.
52. Akahane M, Koga H, Kato N, Yamada H, Uozumi K, Tateishi R, Teratani T, Shiina S, Ohtomo K: Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 2005;25(Suppl 1):S57-S68.
53. Kang TW, Rhim H, Lee MW, Kim YS, Choi D, Lee WJ, Lim HK: Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: comparison of effects of thermal protection and therapeutic efficacy. AJR Am J Roentgenol 2011;196:907-913.
54. Johnson A, Sprangers A, Cassidy P, Heyrman S, Hinshaw JL, Lubner M, Puccinelli J, Brace C: Design and validation of a thermoreversible material for percutaneous tissue hydrodissection. J Biomed Mater Res B Appl Biomater 2013;101:1400-1409.
55. Hasegawa T, Takaki H, Miyagi H, Nakatsuka A, Uraki J, Yamanaka T, Fujimori M, Sakuma H, Yamakado K: Hyaluronic acid gel injection to prevent thermal injury of adjacent gastrointestinal tract during percutaneous liver radiofrequency ablation. Cardiovasc Intervent Radiol 2013;36:1144-1146.
56. Kang TW, Lee MW, Hye MJ, Song KD, Lim S, Rhim H, Lim HK, Cha DI: Percutaneous radiofrequency ablation of hepatic tumours: factors affecting technical failure of artificial ascites formation using an angiosheath. Clin Radiol 2014;69:1249-1258.
57. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, Gazelle GS: Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000;214:761-768.
58. Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ: Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004;28:376-381.
59. Seror O, N'Kontchou G, Tin-Tin-Htar M, Barrucand C, Ganne N, Coderc E, Trinchet JC, Sellier N, Beaugrand M: Radiofrequency ablation with internally cooled versus perfused electrodes for the treatment of small hepatocellular carcinoma in patients with cirrhosis. J Vasc Interv Radiol 2008;19:718-724.
60. Lee JM, Han JK, Kim HC, Kim SH, Kim KW, Joo SM, Choi BI: Multiple-electrode radiofrequency ablation of in vivo porcine liver: comparative studies of consecutive monopolar, switching monopolar versus multipolar modes. Invest Radiol 2007;42:676-683.
61. Woo S, Lee JM, Yoon JH, Joo I, Kim SH, Lee JY, Yoon JH, Kim YJ, Han JK, Choi BI: Small-and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching systemmid-term results. Radiology 2013;268:589-600.
62. Yoon JH, Lee JM, Hwang EJ, Hwang IP, Baek J, Han JK, Choi BI: Monopolar radiofrequency ablation using a dual-switching system and a separable clustered electrode: evaluation of the in vivo efficiency. Korean J Radiol 2014;15:235-244.
63. Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT Jr, Brace CL: Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation-what should you use and why? Radiographics 2014;34:1344-1362.
64. Hwang JH, Crum LA: Current status of clinical high-intensity focused ultrasound. Conf Proc IEEE Eng Med Biol Soc 2009;2009:130-133.
65. Auboiroux V, Petrusca L, Viallon M, Muller A, Terraz S, Breguet R, Montet X, Becker CD, Salomir R: Respiratory-gated mrghifu in upper abdomen using an mr-compatible in-bore digital camera. Biomed Res Int 2014;2014:421726.
66. Lu YC, Chen YJ, Yu YR, Lai YH, Cheng JC, Li YF, Shen CH, Tai CK: Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma. Oncol Rep 2012;28:21-26.
67. Cheon YK, Cho YD, Moon JH, Jang JY, Kim YS, Kim YS, Lee MS, Lee JS, Shim CS: Diagnostic utility of interleukin.
68. (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007;102:2164-2170.
69. Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W, Thomson KR: Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat 2013;12:233-241.
70. Takuma Y, Takabatake H, Morimoto Y, Toshikuni N, Kayahara T, Makino Y, Yamamoto H: Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria. Radiology 2013;269:927-937.
71. Solazzo S, Mertyna P, Peddi H, Ahmed M, Horkan C, Goldberg SN: RF ablation with adjuvant therapy: comparison of external beam radiation and liposomal doxorubicin on ablation efficacy in an animal tumor model. Int J Hyperthermia 2008;24:560-567.
72. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT: Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013;19:3872-3882.
73. Fukuda H, Numata K, Moriya S, Shimoyama Y, Ishii T, Nozaki A, Kondo M, Morimoto M, Maeda S, Sakamaki K, Morita S, Tanaka K: Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation-propensity score matching analysis. Radiology 2014;272:598-604.
74. Xu M, Xie XH, Xie XY, Xu ZF, Liu GJ, Zheng YL, Huang GL, Wang W, Zheng SG, Lü MD: Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo. Acta Radiol 2013;54:199-204.
75. Kudo M: Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011;81(Suppl 1):50-55.
76. Galuppo R, Ramaiah D, Ponte OM, Gedaly R: Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci 2014;59:1688-1697.
77. Poon RT, Borys N: Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011;7:937-945.